04:28 AM EST, 02/21/2025 (MT Newswires) -- Acelyrin ( SLRN ) said late Thursday it has received an unsolicited indication of interest from Tang Capital Partners-backed Concentra Biosciences to acquire all of its outstanding shares for $3.00 per share in cash, plus a contingent value right to receive 80% of net proceeds from any out-license or disposition of its development programs or intellectual property.

Acelyrin ( SLRN ) said it agreed Feb. 6 to an all-stock merger with Alumis (ALMS) in a deal expected to close in Q2.

The company said its board is committed to acting in the interests of shareholders and will make a further announcement on the matter "in due course."

Shares of Acelyrin ( SLRN ) rose more than 12% in recent premarket activity Friday.

Price: 2.45, Change: +0.28, Percent Change: +12.90